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Abstract
Background: Induction of strong T cell responses, in particular cytotoxic T cells, is a key for the generation of
efficacious therapeutic cancer vaccines which yet, remains a major challenge for the vaccine developing world.
Here we demonstrate that it is possible to harness the physiological properties of the lymphatic system to optimize
the induction of a protective T cell response. Indeed, the lymphatic system sharply distinguishes between nanoscale
and microscale particles. The former reaches the fenestrated lymphatic system via diffusion, while the latter either need
to be transported by dendritic cells or form a local depot.
Methods: Our previously developed cucumber-mosaic virus-derived nanoparticles termed (CuMVTT-VLPs) incorporating
a universal Tetanus toxoid epitope TT830–843 were assessed for their draining kinetics using stereomicroscopic imaging.
A nano-vaccine has been generated by coupling p33 epitope as a model antigen to CuMVTT-VLPs using bio-orthogonal
Cu-free click chemistry. The CuMVTT-p33 nano-sized vaccine has been next formulated with the micron-sized
microcrystalline tyrosine (MCT) adjuvant and the formed depot effect was studied using confocal microscopy and
trafficking experiments. The immunogenicity of the nanoparticles combined with the micron-sized adjuvant was next
assessed in an aggressive transplanted murine melanoma model. The obtained results were compared to other
commonly used adjuvants such as B type CpGs and Alum.
Results: Our results showed that CuMVTT-VLPs can efficiently and rapidly drain into the lymphatic system due to their
nano-size of ~ 30 nm. However, formulating the nanoparticles with the micron-sized MCT adjuvant of ~ 5 μM resulted in
a local depot for the nanoparticles and a longer exposure time for the immune system. The preclinical nano-vaccine
CuMVTT-p33 formulated with the micron-sized MCT adjuvant has enhanced the specific T cell response in the stringent
B16F10p33 murine melanoma model. Furthermore, the micron-sized MCT adjuvant was as potent as B type CpGs and
clearly superior to the commonly used Alum adjuvant when total CD8+, specific p33 T cell response or tumour protection
were assessed.
Conclusion: The combination of nano- and micro-particles may optimally harness the physiological properties of the
lymphatic system. Since the nanoparticles are well defined virus-like particles and the micron-sized adjuvant MCT has
been used for decades in allergen-specific desensitization, this approach may readily be translated to the clinic.
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Introduction
Nanoparticles, specifically virus-like particles (VLPs), have
succeeded as prophylactic vaccines and are now widely
used. However, mounting an efficient immune response
by therapeutic cancer vaccines is still a challenging area,
highlighting the need for improved vaccine formulations.
Three main parameters are pivotal for the development of
an effective cancer vaccine: a cancer antigen, a delivery
platform and an adjuvant. A large number of different for-
mulations have been studied extensively in the past years;
however head-to-head comparative data are still scarce
and remain untested in humans [1]. Furthermore, vaccine
formulations have not been studied or optimized with re-
spect to the size of delivery platforms versus adjuvants.
Cucumber-mosaic virus (CuMV) coat protein may be
expressed as a recombinant plant nano-sized virus-like par-
ticle (VLP) and has been studied as a promising candidate
vaccine platform by displaying relevant epitopes for the in-
duction of immune responses [2]. CuMV-VLPs are icosahe-
dral nanoparticles capable of inducing both humoral and
cellular immune responses by generating neutralizing anti-
bodies (Abs), CD4+ TH cells and CD8
+ cytotoxic T lympho-
cytes (CTLs) [3, 4]. Previously, we have developed an
engineered nano-sized cucumber-mosaic virus-derived VLP
by incorporating a universal Tetanus toxoid epitope TT830–
843 which we termed CuMVTT-VLPs [5]. The incorporation
of the universal T cell epitope has been shown to be a
powerful enhancer of the immune response in Tetanus tox-
oid immunized mice. Using the engineered nano-sized
CuMVTT-VLPs as a vaccine platform in humans is also ex-
pected to enhance their immune responses, since this epi-
tope is recognized in essentially all humans who all have
memory CD4+ T cells specific for the epitope due to vaccin-
ation against tetanus [5]. We have shown in several studies
that CuMVTT-VLPs nano-vaccine induce protective and
therapeutic Ab responses in mice, horses and dogs [5–7].
Depot-forming adjuvants can prolong antigen presenta-
tion time to antigen-presenting cells (APCs), protect anti-
gen from degradation and are optimal for T cell
enhancement and clonal expansion [8, 9]. Microcrystalline
tyrosine (MCT) is a classical adjuvant used in the niche
area of allergy immunotherapy, some of which include
products that are licensed or are currently in late stage clin-
ical development [10]. MCT forms crystals of natural
L-Tyrosine and due to their micron-size, they cannot read-
ily enter the lymphatics and remain at the injection site,
forming a depot and local inflammation [11]. The introduc-
tion of MCT as a depot was based on its favorable bio-
degradable properties where a 48 h half-life at the injection
site has been previously reported, making it suitable to
adapt within formulations designed for weekly-dose
administration as is also often used for cancer vac-
cines [11–14]. Moreover, early immunological studies
in various animal models showed a more favorable
TH1-biased immunological profile compared with the
widely used Alum adjuvant [12, 15]. This is also fur-
ther indicated where immunological synergy is ob-
served when MCT is combined with Monophosphoryl
Lipid A®, since it was shown that a combination of
MCT and MPL was synergistic in enhancing murine
antigen specific IgG Ab responses without increasing
antigen specific IgE responses [15]. A short-course
allergy vaccine using this adjuvant combination has
recently completed a successful Phase II study in
Europe and has been marketed as a named patient
product for a number of years [16]. Further evidence
has now emerged on MCT’s more specific immuno-
modulatory functions. MCT activates the inflamma-
some in vitro and has been demonstrated to induce
sustained and robust innate responses, including, spe-
cific adaptive T cell responses in a variety of immune-
applications [11, 13, 14]. Consequently, proof of
concept studies using MCT across a broader vaccine
scope is being pursued more rigorously and has since
highlighted its adaptable nature within various formu-
lation designs with other adjuvants / delivery systems
in optimizing immune responses [17].
Here we harnessed the influence of particle’s size on
draining properties and their efficacy in producing effective
CTLs response against an aggressive B16F10 tumour model
by combining a CuMVTT nano-vaccine with the micron-
size MCT adjuvant. We compared the response to other
commonly used adjuvants such as the well-established
Alum and the potent B type immunostimulatory CpGs. We
show that the micron-sized MCT is a powerful adjuvant for
CuMVTT-p33 nano-vaccine displaying p33 epitope derived
from LCMV, rivaling CpGs and clearly performing better
than Alum in inducing CTLs and tumour protection. Thus,
this combination may be an optimal way to formulate
cancer nano-vaccines with micron-sized adjuvants thereby
taking advantage of the physiological properties of the
lymphatic system.
Materials and methods
Expression and production of CuMVTT-VLPs
CuMVTT-VLPs expression and production was performed
as described in detail in [5].
Electron microscopy
Physical stability and integrity of CuMVTT-VLPs were
visualized by transmission electron microscopy using the
Philips CM12 EM. For imaging, sample-grids were glow
discharged and 5 μl of VLP solution was added for 30 s.
The grids were then washed 3x with ddH2O and nega-
tivly stained with 5 μl of 5% uranyl acetate for 30 s. Fi-
nally, excess uranyl acetate was removed by pipetting
and the grids were air dried for 10 min. Images were
taken with 84,000x and 110,000x magnification.
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Mice
Wild type C57BL/6 mice were purchased from Harlan.
RAG2−/− mice on a C57BL/6 background were provided
by Ochsenbein’ lab and were bred in our pathogen-free
animal facility. All in vivo experiments used 8–12-week-old
female. All animal procedures were performed in accord-
ance with the Swiss Animals Act (455.109.1) (September
2008, 5th) of University of Bern.
Stereomicroscopic imaging
WT C57BL/6 mice (8–12 weeks; Harlan) were anesthe-
tized and prepared for imaging by shaving their right leg.
Skin and adipose tissues were removed to expose the pop-
liteal lymph node (LN) as described in detail in [18]. The
anesthetized mice were then stabilized on a customized
platform for imaging. The popliteal LN was located by
bright field illumination imaging. A dose of 10 μg of
CuMVTT-VLPs vaccine was labelled with Alexa Fluor 488
(AF488) according to the manufacturer’s instructions
(Thermo Fisher SCIENTIFIC) and injected subcutane-
ously (s.c.) into the mouse footpad to study the draining
kinetics of CuMVTT-VLPs. Fluorescent light illumination
with a CCD Nikon camera was used for imaging.
Development of CuMVTT-p33 nano-vaccine using bio-
orthogonal cu-free click chemistry
CuMVTT-VLPs were derivatized using 10-fold molar ex-
cess of DBCO cross-linker (Dibenzocyclooctyne-N-hy-
droxysuccinimidyl ester) (Sigma-Aldrich) in 2 mM
EDTA and 20 mM NaP, pH 7.5 for 30 min at RT in a
shaker at 400 rpm. Excess uncoupled DBCO was re-
moved by diafiltration steps. Modified p33 peptide
H-KAVYNFATMGGCK(N3)-NH2 was purchased from
(Pepscan PRESTO) and reconstituted using DMSO.
10-fold molar excess of the modified peptide was then
added to the derivatized CuMVTT-VLPs. 5-fold molar
excess of TCEP was added to liberate cysteine residues
at the C-terminus on the VLPs. The coupling was
performed for 1 h at RT in a shaker at 400 rpm. Excess
peptide was removed using 100 kDa MWCO amicon
centrifuge tubes (Sigma Aldrich). The efficiency of the
coupling was tested by SDS-PAGE (Bio-RAD) and
assessed by densitometric analysis of SDS-PAGE of Cu
MVTT-VLP monomer bands compared to CuMVTT-VLP
monomer plus p33 after coupling.
Depot effect with confocal microscopy
10 μg of AF488 CuMVTT-p33 nano-vaccine formulated
or not formulated with 50 μl of 4% MCT adjuvant was
injected in WT C57BL/6 mice footpads (8–12 weeks;
Harlan) using isoflurane anesthesia. Popliteal LNs were
collected 3 h, 24 h, 48 h, 96 h and 216 h after injection.
Lymph nodes were fixed in PFA 2% for 3 h at RT. The
LNs were transferred to CUBIC 1 medium [19] for 8
days at 37 °C and scanned at Leica SP8 with 10x lense,
1024 × 1024 resolution, tile scan was performed in LNs
that were not fitting in the field of view of the 10x lense.
Images were analyzed and segmented the individual
CMV particles using Imaris Software v9.2.1 (Bitplane).
Depot effect with trafficking experiment
10 μg of AF488 CuMVTT-p33 nano-vaccine formulated or
not formulated with 50 μl of 4% MCT adjuvant was
injected in WT C57BL/6 mice footpads (8–12 weeks; Har-
lan) using isoflurane anesthesia. Popliteal LNs were col-
lected 3 h, 24 h, 48 h, 96 h and 216 h after injection and
treated with collagenase D (Roch) in 10%FSC containing
DMEM for 25min at 37 °C. Cells were stained with live/
dead dye (eBioscience) and analyzed for total number of
FITC+ (CuMVTT-p33). Naïve mice were used as a control.
Measuring p33 specific CD8+ T cell response in the spleen
Six groups of WT C57BL/6 mice (8–12 weeks old; Harlan)
were vaccinated s.c. with a single dose of: 1st group 70 μg
of CuMVTT-VLPs, 2nd group 70 μg of CuMVTT-Actin
nano-vaccine, 3rd group 70 μg of CuMVTT-p33 nano-vac-
cine, 4th group 70 μg of CuMVTT-p33 nano-vaccine
admixed with 15 nmol of B type CpGs 5′′-TCC ATG ACG
TTC CTG ATG CT-3′′) (20 mer) (Invivogen), 5th group
70 μg of CuMVTT-p33 nano-vaccine formulated with 4%
MCT adjuvant (40mg/ ml) (Allergy Therapeutics Ltd.
Worthing, UK) and the 6th group 70 μg of CuMVTT-p33
nano-vaccine formulated with 100 μl of Alhydrogel
adjuvant 2% (InvivoGen). Formulating CuMVTT-p33 with
MCT or Alum requires prolonged mixing of both
components for 1 h at RT in shaker at 400 rpm to ensure
adequate adsorption of the VLPs on MCT or Alum surface.
Seven days later, spleens were collected and staining was
performed using Fc-block, live/dead, anti-CD8 (eBioscience)
and p33 (KAVYNFATM) tetramer designed using H-2Db
allele and PE fluorochrome (TCMetrix).
Intra-cellular cytokine (ICS) staining for IFN-γ and TNF-α
Intra-cellular cytokine staining was performed on
spleens and TILs of vaccinated WT C57BL/6 mice for
measuring of IFN-γ and TNF-α cytokines as described
in detail in [20].
Tumour experiments
1 × 106 cells of B16F10p33 melanoma cell line (From
Ochsenbein lab) was injected into the flank of RAG2−/−
C57BL/6 mice (From Ochsenbein lab). Twelve days later
the growing tumours were collected and processed into
~2mm2 fragments for transplantation into the flank of
WT C57BL/6 mice (8–12 weeks old; Harlan) under full
anesthesia. The transplanted WT C57BL/6 mice were
treated 3 times over 14 days (mice in the control group
reached the humane end-point at day 14). In the first
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tumor experiment mice were vaccinated s.c. as follows:
1st group 70 μg of CuMVTT-VLPs, 2nd group 70 μg of
CuMVTT-p33 nano-vaccine and 3rd group 70 μg of
CuMVTT-p33 nano-vaccine formulated with 4% MCT
adjuvant (40 mg/ ml) (Allergy Therapeutics Ltd. Wor-
thing, UK). In the second tumour experiment mice were
vaccinated s.c. as follows: 1st group 70 μg of CuM
VTT-VLPs, 2nd group 70 μg of CuMVTT-p33 nano-vac-
cine admixed with 15 nmol of B type CpGs 5′′-TCC
ATG ACG TTC CTG ATG CT-3′′) (20 mer) (Invivo-
gen), 3rd group 70 μg of CuMVTT-p33 nano-vaccine
formulated with 4% MCT adjuvant (40 mg/ ml) (Allergy
Therapeutics Ltd. Worthing, UK) and 4th group 70 μg
of CuMVTT-p33 nano-vaccine formulated with 100 μl of
Alhydrogel adjuvant 2% (InvivoGen). Tumour growth
was followed daily and measured using calipers. Tu-
mours were collected and measured on day 14. TILs
were isolated by treating the tumours with collagenase D
(Roch) in 10%FSC containing DMEM for 25 min at 37 °
C. Cells were passed through a cell strainer of 100 μm
(Corning) and TILs were separated using Ficoll (Sig-
ma-Aldrich). TILs were stained with Fc block, live/dead,
anti-CD8 (eBioscience) and p33 tetramers (TCMetrix).
Statistics
Tumour growth curves were compared by calculating
the area-under curve (AUC) and analyzed by One-Way
ANOVA (Turkey’s Multiple Comparison Test). Other
data has been analyzed and presented using Unpaired
Student’s t test. GraphPad Prism7 or 8 software was used
for the analysis.
Results
CuMVTT-VLPs demonstrate fast kinetics and constitute an
efficient vaccine platform for displaying target peptides/
epitopes
In a first step, we produced the engineered CuMVTT-VLPs
and confirmed their morphology, integrity and nano-size
by electron microscopy (Fig. 1a). Next, we studied the
draining-kinetics of CuMVTT-VLPs utilizing stereomiscro-
scopic imaging. To this end, CuMVTT-VLPs were labelled
with the fluorescent dye AF488 and injected s.c. in the
footpad of WT C57BL/6 mice. Our results show that the
labelled nanoparticles accumulate in the popliteal LN in
less than 1min, demonstrating fast and efficient draining
of free 30 nm CuMVTT-VLPs (Fig. 1b). To study the effi-
cacy of CuMVTT-VLPs as a cytotoxic T cell based nano-
vaccine, we have used the H-2Db restricted p33 peptide
derived from LCMV as a model antigen. The model pep-
tide was coupled to CuMVTT-VLPs using our developed
method based on “biorthogonal Cu-free click chemistry”
as illustrated in Fig. 1c. The efficiency of the coupling was
tested using SDS-PAGE. The additional bands above the
VLP monomer show efficient coupling of p33 peptide to
CuMVTT-VLP monomers (Fig. 1d).
The micron-sized MCT adjuvant displays depot effect
when combined with CuMVTT-p33 nano-vaccine
Microcrystalline tyrosine (MCT) is considered to be a
depot-forming adjuvant facilitating the slow but prolonged
release of antigens. Formulating the nano-vaccine
CuMVTT-p33 with the micron-sized MCT adjuvant may
therefore enhance the slow release of the nanoparticles dis-
playing the target epitope and extend their exposure to the
immune system. To test that, we have first formulated the
AF488 CuMVTT-p33 nano-vaccine with MCT in vitro to
visualize the binding of the nanoparticles to the
micron-sized MCT adjuvant by confocal microscopy. The
results showed that the labelled nanoparticles bind and dec-
orate the surface of the micron-sized crystals (Fig. 2a). To
further study this hypothesis in vivo, we injected the AF488
CuMVTT-p33 nano-vaccine (alone or formulated with
MCTadjuvant) into the footpad of WT C57BL/6 mice as il-
lustrated in Fig. 2b and collected the popliteal LNs at differ-
ent time-points 3 h, 24 h, 48 h, 96 h and 216 h to assess the
persistence of the labelled nanoparticles by flow cytometry.
The results demonstrate that CuMVTT-p33 injected in free
form disappears from the popliteal LN in ~ 4 days while
formulating the nano-vaccine with the micron-sized MCT
adjuvant causes slower but prolonged release of the nano-
particles over 9 days (Fig. 2c). These findings were also
supported when imaging the popliteal LNs by confocal
microscopy (Fig. 2d).
Formulating CuMVTT-p33 nano-vaccine with the micron-
sized MCT adjuvant induces significant p33 specific T cell
response and enhances cytokines secretion
We then tested whether formulating CuMVTT-p33
nano-vaccine with MCT would enhance the specific T
cell response in vivo. Therefore, six vaccines and formu-
lations were prepared as outlined in Fig. 3a. CpG 1668
and Alum were independently formulated with
CuMVTT-p33 nano-vaccine to benchmark the potency
of the micron-sized MCT adjuvant. Actin coupled to
CuMVTT-VLPs was used as a non-specific control
peptide to show that the obtained response is specific to
p33 peptide. The different vaccine formulations were
injected once s.c. in WT C57BL/6 mice and spleens were
collected seven days later for tetramer and intra-cellular
cytokine staining. The H2-Db allele p33 (KAVYNFATM)
tetramers have been used to enable direct visualization
and quantification of p33 specific T cells. The results
showed that admixing CuMVTT-p33 nano-vaccine with
CpGs 1668 or formulating it with the micron-sized
MCT adjuvant induced the highest percentage of p33
specific T cells upon single injection (Fig. 3b and f). We
then assessed the cytokine secretion in each group,
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mainly IFN-γ and TNF-α. The secretion of both cyto-
kines was enhanced when combining the nano-vaccine
with CpGs 1668 or MCT adjuvant (Fig. 3c and d). Formu-
lating CuMVTT-p33 nano-vaccine with Alum did not en-
hance the production of p33 specific T cells nor the
secretion of IFN-γ or TNF-α. Furthermore, when analyzing
the dual secretion of IFN-γ and TNF-α in polyfunctional T
cells, a large percentage of the cytokine-producing T cells
was found to be polyfunctional in the groups admixed with
CpGs 1668 or MCT (Fig. 3e and g).
Formulating CuMVTT-p33 nano-vaccine with the micron-
sized MCT adjuvant delays tumour growth and enhances
CD8+ and p33 specific CTL infiltration into B16F10p33
tumours
In order to test the immunogenicity and efficacy of com-
bining nanoparticles with micron-sized adjuvants in a
melanoma model, we have adapted a challenging melan-
oma murine model based on transplanting ~2mm3 of
B16F10p33 tumour fragment into the flank of WT
C57BL/6 mice. The tumour was allowed to grow for 5
days more following transplantation before the vaccin-
ation regimen started (Fig. 4a). Three groups were pre-
pared as illustrated in Fig. 4b, CuMVTT-VLPs as a
control, CuMVTT-p33 nano-vaccine alone and CuM
VTT-p33 nano-vaccine formulated with MCT. Tumours
were collected for analysis 14 days after tumour trans-
plantation as the control group reached the ethically
allowed maximal size of ~1000mm3. The obtained
results revealed that formulating CuMVTT-p33 nano-
vaccine with the micron-sized MCT could significantly
hinder B16F10p33 tumour progression when compared
to the control group (p < 0.0001) or to the group vacci-
nated with CuMVTT-p33 nano-vaccine alone (p 0.0055)
Fig. 1 CuMVTT-VLPs demonstrate fast kinetics and constitute an efficient vaccine platform for displaying target peptides/epitopes. a Electron
microscopy imaging of CuMVTT-VLPs, (3.5mg/ml) adsorped on carbon grids and negatively stained with uranyl acetate solution, scale bar 200 nm,
CuMVTT-VLPs sized ∼30 nm. b Stereomicroscopy images of mice popliteal LN following s.c. injection of AF488 CuMVTT-VLPs in mice footpad. [1] bright
field of the popliteal LN (identified by the arrowhead) [2] fluorescent image prior to injection of AF488 CuMVTT-VLPs, [3–5] 1min, 5 min and 10min
post injection of AF488 CuMVTT-VLPs taken with the appropriate fluorescent filters. c A sketch illustrating the coupling of p33 epitope to CuMVTT-VLPs
using Cu-free click chemistry (Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DBCO) cross-linker). DBCO cross-linker reacts with Lys residues on
CuMVTT-VLPs and incorporates a cyclooctyne moiety. The formed dibenzocyclooctyne will then react with azide-labelled p33 peptide forming a stable
triazole linkage without Cu catalyst. d SDS-PAGE of CuMVTT-p33 nano-vaccine using DBCO “Dibenzocyclooctyne-N-hydroxysuccinimidyl ester” cross-
linker; arrows indicate CuMVTT-VLP monomers and dimers (formed by DBCO cross-linking of 2 monomers) with coupled p33 peptide
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(Fig. 4c and d). Tumour-infiltrating lymphocytes (TILs)
represent a prognostic factor for effective immune responses
especially in melanoma [21, 22]. Therefore, we measured the
total number of the infiltrated CD8+ T cells and p33 specific
CTLs (Fig. 4e) in TILs and calculated the density of these
cells in each vaccinated group (number of cells divided by
tumour volume). Formulating CuMVTT-p33 nano-vaccine
with MCT significantly increased the density of total CD8+
T cells (p. 0.0024) (Fig. 4f) as well as the density of p33 spe-
cific CTL measured by tetramers (p. 0.0093) (Fig. 4g) in
comparison to mice vaccinated with CuMVTT-p33 nano-
vaccine alone. IFN-γ production was also enhanced when
formulating CuMVTT-p33 with MCT (Fig. 4h). Thus, for-
mulating the a nano-vaccine in MCT enhanced infiltration
by specific T cells as well as anti-tumor protection.
The micron-sized MCT adjuvant shows comparable
activity to B-type CpGs and is superior to alum in driving
protection against B16F10p33 melanoma
The immunogenicity of the CuMVTT-p33 nano-vaccine
formulated with the micron-sized MCT adjuvant was
then compared to the immune-stimulatory B type CpGs
and the widely used adjuvant Alum using the same ag-
gressive B16F10p33 tumour model. Four groups were
prepared as shown in Fig. 5a. The results again revealed
that formulating CuMVTT-p33 nano-vaccine with CpGs
1668 or MCT would significantly (p 0.0072, 0.0129 re-
spectively) hinder B16F10p33 tumour progression,
which was not the case when formulating CuMVTT-p33
with Alum (p 0.4188) (Fig. 5b). In a next step, we mea-
sured the total number of infiltrated CD8+ T cells (Fig.
5c) and p33 specific CTLs (Fig. 5d) in the tumour and
calculated the density. There was a general increase in
the groups mixed with CpGs 1668 or formulated with
MCT or Alum (Fig. 5e and f). Formulating
CuMVTT-p33 nano-vaccine with the micron-sized MCT
adjuvant showed comparable results to CpGs 1668, the
gold standard adjuvant in mice. Furthermore, MCT ad-
juvant was more potent at increasing the infiltration of
total CD8+ and p33-specific T cells into the tumour
microenvironment when compared to formulating the
vaccine with Alum.
Fig. 2 The micron-sized MCT adjuvant displays depot effect when combined with CuMVTT-p33 nano-vaccine. a Confocal microscopy imaging of
AF488 CuMVTT-p33 nano-vaccine following formulation with the micron-sized MCT adjuvant, 1) GFP signal of AF488 CuMVTT-p33 nano-vaccine 2)
bright light field 3) an overlay 4–6 3D images with bright light field 4) an MCT crystal decorated with CuMVTT-p33 nano-vaccine particles. b A
sketch illustrates the two prepared nano-vaccines, the 1st group consists of AF488 CuMVTT-p33 nano-vaccine and the 2nd consists of AF488
CuMVTT-p33 nano-vaccine formulated with MCT adjuvant. d Total number of AF488 CuMVTT-p33 nanoparticles in the popliteal LNs collected 3 h,
24 h, 48 h, 96 h and 216 h post-injection of the two prepared nano-vaccine groups in mice footpad. Statistical analysis by unpaired Student’s t
test. c Confocal microscopy images of popliteal LNs 24 h and 216 h post-injection of the two prepared nano-vaccine groups in mice footpad, GFP
signal was detected in LNs, whole mount view of z-stacks was acquired. One representative experiment of 3 similar experiments is shown
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The micron-sized MCT adjuvant shows comparable
production of cytokines to B type CpGs and is superior to
alum in B16F10p33 melanoma
Production of IFN-γ and TNF-a cytokines by TILs was
also assessed upon immunization with CuMVTT-p33
admixed with B type CpGs or formulated with MCT or
Alum. Production of IFN-γ (Fig. 6a and b) and TNF-a
(Fig. 6c and d) was assessed separately or as dual cytokine
production in polyfunational T cells (Fig. 6e and f). There
was no significant difference in the production of single
IFN-γ, TNF-a or dual IFN-γ/TNF cytokines between the
groups admixed with CpGs 1668 or formulated with
MCT adjuvant (p 0.3986, 0.3433 and 0.4120 respectively).
However, there was a significant difference when compar-
ing the group formulated with MCT to the one formu-
lated with Alum (p 0.0179, 0.0187 and 0.006, respectively).
Discussion
In this study, we have developed cucumber mosaic
virus-derived nanoparticles genetically fused to the
universal T cell epitope of Tetanus toxin (CuM
VTT-VLPs). These nanoparticles constitute a promis-
ing vaccine platform as the incorporated Tetanus
toxin epitope can enhance their immunogenicity and
the production of robust Ab and CTL responses espe-
cially in aging populations [5, 6]. Displaying epitopes
on CuMVTT-VLP’s exterior surface can be achieved
by simple chemical techniques such as the SMPH
heterobifunctional cross-linker. Such techniques have
shown efficacy and good results in many different
clinical settings [23–25]. However, we have lately en-
hanced the coupling efficacy of epitopes to bacterio-
phage Qβ-VLP using the biorthogonal Cu-free click
chemistry (Mohsen et al., submitted). Here we have
shown that such method can also be efficiently used
to couple peptides/epitopes to CuMVTT-VLPs. Gener-
ally, Cu-free click chemistry is a safe, non-toxic coup-
ling method as the azide moiety attached to the
target epitope does not react with any of the body’s
natural molecules [26–28].
Fig. 3 Formulating CuMVTT-p33 nano-vaccine with the micron-sized MCT adjuvant induces significant p33 specific T cell response and enhances
cytokines secretion. a Vaccination scheme for six vaccine groups, CuMVTT-VLPs, CuMVTT-Actin, CuMVTT-p33, CuMVTT-p33 admixed with CpG 1668,
CuMVTT-p33 formulated with MCT and CuMVTT-p33 formulated with Alum. b Percentage of CD8
+ Tetramer+ CTLs (means ± SEM) in the spleen in
each vaccinated group. c Percentage of CD8+ IFN-γ+ secreting cells (means ± SEM) in the spleen in each vaccinated group. d Percentage of
CD8+ TNF-α+ cells (means ± SEM) in the spleen in each vaccinated group. e Percentage of CD8+ IFN-γ+/TNF-α+ secreting cells (means ± SEM) in
the spleen in each vaccinated group. Statistical analysis by Oneway ANOVA (Turkey’s Multiple Comparison Test). f Representative flow cytometry
dot plots showing the percentage of CD8+ Tetramer+ CTLs in each vaccinated group. g Representative flow cytometry dot plots showing the
percentage of CD8+ IFN-γ+/TNF-α+ secreting cells in each vaccinated group. (3 mice per group), one representative of 3 similar experiments
is shown
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Immunostimulatory adjuvants such as synthetic
CpG-oligonucleotides are TLR-agonists and have shown
promising therapeutic potential by activating both the
innate and adaptive immune system [29–31]. CpGs have
also been successfully used clinically to adjuvant cancer
vaccines [32, 33]. However, CpGs have some drawbacks
including their unfavourable pharmacokinetics and their
propensity to cause splenomegaly, at least in mice [34,
35]. It has been shown previously that packaging CpGs
into VLPs such as Qβ or HBcAg can improve the
pharmacokinetics and dynamics of the DNA oligomers
[36]. Nevertheless, it is not always feasible to package
VLPs with CpGs as some nanoparticles are unstable and
packaging with reassembly processes may be time con-
suming when targeting translational approaches. Fur-
thermore, TLR-9 agonists have been widely used with
VLP-based vaccines to enhance T and B cell responses
mostly in mice and more rarely in humans [37]. In mice,
TLR-9 is expressed by all DCs while in human it is
mainly expressed by pDCs in lymphoid organs but not
by conventional DCs [38]. pDCs, however, respond
much more efficiently to A type CpGs rather than B
type CpGs as only the former induce strong production
of type I IFN [39]. Hence, it may be difficult to directly
translate findings with B type CpGs from mice to
humans. With this respect, it is interesting to note that
CuMVTT VLPs naturally package RNA from the E. coli
expression strain, a ligand for TLR7/8 which is
expressed in all human DCs.
Several preclinical and clinical studies have indicated
that some of the adjuvants used in licensed products are
not optimal for developing effective cancer vaccines. Ex-
amples are the commonly used Montanide (Incomplete
Freund’s adjuvant) and Alum [40–43]. Such limitations
Fig. 4 Formulating CuMVTT-p33 nano-vaccine with the micron-sized MCT adjuvant causes tumour regression and enhances CD8
+ and p33
specific CTL infiltration into B16F10p33 tumours. a A diagram illustrating the adapted tumour experimental method based on injecting ~ 1 × 106
B16F10p33 melanoma cell line into the flank of RAG2−/− deficient C57BL/6 mice. Twelve to thirteen days later the growing tumours were
collected and processed in ~2mm3 for transplantation into the flank of WT C57BL/6. b Vaccination scheme for three vaccine groups, CuMVTT-
VLPs, CuMVTT-p33 and CuMVTT-p33 formulated with MCT. c Tumour growth curve of subcutaneous B16F10p33 melanomas in each vaccinated
group, mice were euthanized when the tumour reached ~1000mm3, arrows indicate start of treatment. d Tumour volume mm3 (mean ± SEM)
measured at day 14 post tumour collection in each vaccinated group, each dot represents a tumour. e Representative flow cytometry dot plots
showing the total number of CD8+ Tetramer+ CTLs in each vaccinated group. f Density of CD8+ T cells (means ± SEM) in each vaccinated group,
“measured by dividing the total number of CD8+ cells in TILs by the tumour volume”. g Density of CD8+ Tetramer+ CTLs (means ± SEM) in each
vaccinated group, “measured by dividing the total number of CD8+ Tetramer+ CTL by tumour volume”. h Percentage of CD8+ IFN-γ + secreting
cells (means ± SEM) in each vaccinated group. Statistical analysis by Student’s t test. (5 mice per group), one representative of 3 similar
experiments is shown
Mohsen et al. Journal for ImmunoTherapy of Cancer           (2019) 7:114 Page 8 of 12
may include the inadequate ability of these adjuvants to
induce CTLs [44]. Nevertheless, use of B-type CpGs and
Alum in mice is useful where direct comparative adju-
vant studies are concerned. Since they are well charac-
terized in mice, both adjuvants are a good benchmark
when comparing other new or newly used adjuvants
such as MCT.
MCT is a micron-sized adjuvant that forms crystals of
about ~ 5 μM that readily adsorb proteins including
protein-based nanoparticles such as VLPs. MCT is well
known in the world of specific allergy immunotherapy,
as it is categorized as a depot excipient in registered sub-
cutaneous immunotherapy products for the treatment of
allergies. However, the knowledge about its mechanism
of action and its potential in different fields of vaccinol-
ogy is only expanding now. In a recent study, MCT was
shown to be an effective adjuvant in allergen-specific
immunotherapy. Protection against IgE-mediated allergic
response was achieved in mouse models, independently
of inflammasome and TLR signaling in vivo. As has been
seen for Alum, the adjuvant activity of MCT was inde-
pendent of the inflammasome in vivo despite its ability
to activate the inflammasome in vitro [11]. In malaria,
MCT has been shown to consistently enhance protective
IgG responses and more protective IgG subclasses
resulting in enhanced protection against malaria. Similar
observations were made for influenza vaccine candidates
[13, 14, 17].
Here, we have studied the draining kinetics of
CuMVTT-p33 vaccine alone or formulated with adjuvant
MCT. Our results indicate that the free AF488
CuMVTT-p33 can drain rapidly into the draining LN but
fades away after ~ 4 days. In contrast, the release of
AF488 CuMVTT-p33 nano-vaccine formulated with
Fig. 5 The micron-sized MCT adjuvant shows comparable activity to B type CpGs and is superior to Alum in driving protection against
B16F10p33 melanoma. a vaccination scheme for four vaccine groups, CuMVTT-VLPs, CuMVTT-p33 admixed with CpG 1668, CuMVTT-p33 formulated
with MCT and CuMVTT-p33 formulated with Alum. b Tumour growth curve of subcutaneous B16F10p33 melanomas in each vaccinated group,
mice were euthanized when the tumour reached ~1000mm3, arrows indicate start of treatment. c Representative flow cytometry dot plots
showing the total number of CD8+ T cells in each vaccinated group, gated on TILs. d Representative flow cytometry dot plots showing the total
number of CD8+ Tetramer+ CTLs in each vaccinated group, gated on CD8+ T cells. e Density of CD8+ T cells (means ± SEM) in each vaccinated
group, “measured by dividing the total number of CD8+ cells in TILs by the tumour volume”. f Density of CD8+ Tetramer+ CTLs (means ± SEM) in
each vaccinated group, “measured by dividing the total number of p33 tetramer+ CTLs by tumour volume”. Statistical analysis by Student’s t test.
(4 mice per group), one representative of 3 similar experiments is shown
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MCT was delayed and more consistent over a longer
period of time. Previous studies have mostly supported
the importance of the depot-forming adjuvants in T cell
based vaccine development as they delay the clearance
of the vaccine that results in enhancing the generation
of effective antigen-specific CTL responses [45, 46].
To study the immunogenicity of the developed
CuMVTT-p33 nano-vaccine formulated with MCT, the
protective capacity of the induced CTL-responses was
assessed in an aggressive murine melanoma model con-
sisting of B16F10 cells transfected with H-2Db restricted
p33 epitope derived from LCMV. To generate tumors
with maximal physiological properties, we have used a
challenging tumour model based on transplanting solid
tumour fragments rather than single cell suspension.
The transplantation of solid tumor fragments allows
studying tumor development in the context of already
established tumor stroma which is more reflective of the
physiological situation. When transplanted as solid frag-
ments, even very immunogenic tumors grow in im-
munocompetent hosts and the vascularized tumours
rapidly grow to lethal size (47–50). The results show that
formulating CuMVTT-p33 nano-vaccine with MCT was
more potent in blocking tumour growth than using the
nano-vaccine alone. The protective capacity of the
CuMVTT-p33 with MCT is therefore strong, as the
model used is very challenging. Previous studies have in-
dicated that melanoma tumours exhibiting increased
numbers of tumour infiltrating CD8+ T cells have better
prognosis. TILs have led to a better understating of the
Fig. 6 The micron-sized MCT adjuvant shows comparable production of cytokines to B type CpGs and is superior to Alum in B16F10p33
melanoma. a Percentage of CD8+ IFN-γ + secreting cells (means ± SEM) in each vaccinated group. b Representative flow cytometry dot plots
showing the frequency of CD8+ IFN-γ+ secreting cells in each vaccinated group. c Percentage of CD8+ TNF- + secreting cells (means ± SEM) in
each vaccinated group. d Representative flow cytometry dot plots showing the frequency of CD8+ TNF- + secreting cells in each vaccinated
group. e Percentage of dual IFN-γ+ and TNF- + secreting cells (means ± SEM) in each vaccinated tumour, gated on CD8+ cells in TILs. f
Representative flow cytometry dot plots showing the frequency of dual IFN-γ+ and TNF- + secreting cells in each group, gated on CD8+ cells in
TILs. Statistical analysis by Student’s t test. (4 mice per group), one representative of 3 similar experiments is shown
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interaction between hosts and tumours, mainly because
their study allowed better characterization of effective
therapeutic responses [22, 47]. TILs isolated from the
vaccinated groups have been assessed for the presence
of p33 specific CTLs by means of tetramers and intracel-
lular cytokine staining. CuMVTT-p33 vaccine formulated
with MCT adjuvant enhanced the infiltration of CD8+
and p33 specific CTLs into the tumour and the produc-
tion of IFN-γ. These results indicate that MCT may be a
promising cancer adjuvant. When comparing MCT adju-
vant to the potent B type CpGs or the widely used Alum,
the overall adjuvants activity of MCT was comparable to
CpGs and superior to Alum.
It has been previously seen that Alum may increase over-
all IgG responses at least as good as MCT. In contrast to
Alum, however, MCT induced superior IgG2a responses,
which is usually associated with TH1 responses and/or TLR
activity [14]. This may be compatible with the observed
ability of MCT to enhance CTL responses, which Alum
failed to do. Further work will be required to elucidate the
mechanism of this difference, as both Alum and MCT form
a depot and may activate the inflammasome pathway. An
obvious hypothesis is that Alum induces a TH2 driving
pathway in addition to the inflammasome or vice versa,
MCT may activate a TH1 driving pathway. The distinctions
portrayed in their respective immunological profiles are
also likely to be be partly governed by their inherent formu-
lation/structural characteristics (i.e. particle size, morph-
ology, antigen adsorption etc). In addition to this, it is
known that tryptophan or arginine serve as direct
immune-modulators, a possibility that has not been exten-
sively studied for tyrosine [48, 49].
Taken together, this study shows that MCT is a potent
enhancer of CTL responses and may be viewed as a
multi-purpose adjuvant with novel indications. As such,
its effectiveness and compatibility in a mix- and match
adjuvant systems approach should be further tested in
preclinical and human immunotherapy trials. Combin-
ation of MCT with nanoparticles appears particularly at-
tractive, as the micron-sized adjuvants will form a local
depot at the injection site with concomitant activation of
skin-resident antigen-presenting cells. Nanoparticles will
be released over time, draining to local LNs for extended
time-periods, causing an optimal immune reaction.
Thus, the combination of nanoparticles with micron-
sized adjuvants may optimally harness the properties of
the lymphatic system.
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